BRPI1008020A2 - antagonistas e agonistas inversos h3 da histamina e métodos de uso dos mesmos - Google Patents
antagonistas e agonistas inversos h3 da histamina e métodos de uso dos mesmosInfo
- Publication number
- BRPI1008020A2 BRPI1008020A2 BRPI1008020A BRPI1008020A BRPI1008020A2 BR PI1008020 A2 BRPI1008020 A2 BR PI1008020A2 BR PI1008020 A BRPI1008020 A BR PI1008020A BR PI1008020 A BRPI1008020 A BR PI1008020A BR PI1008020 A2 BRPI1008020 A2 BR PI1008020A2
- Authority
- BR
- Brazil
- Prior art keywords
- histamine
- antagonists
- methods
- inverse agonists
- agonists
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15181709P | 2009-02-11 | 2009-02-11 | |
| PCT/US2010/000335 WO2010093425A1 (en) | 2009-02-11 | 2010-02-11 | Histamine h3 inverse agonists and antagonists and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1008020A2 true BRPI1008020A2 (pt) | 2016-03-15 |
Family
ID=42084672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1008020A BRPI1008020A2 (pt) | 2009-02-11 | 2010-02-11 | antagonistas e agonistas inversos h3 da histamina e métodos de uso dos mesmos |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8063032B2 (pt) |
| EP (1) | EP2396327A1 (pt) |
| JP (1) | JP2012517471A (pt) |
| KR (1) | KR20110132564A (pt) |
| CN (1) | CN102388043A (pt) |
| AU (1) | AU2010214101A1 (pt) |
| BR (1) | BRPI1008020A2 (pt) |
| CA (1) | CA2752073A1 (pt) |
| IL (1) | IL214501A0 (pt) |
| RU (1) | RU2011137419A (pt) |
| SG (1) | SG173639A1 (pt) |
| WO (1) | WO2010093425A1 (pt) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101712576B1 (ko) | 2008-11-10 | 2017-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| PL3354650T3 (pl) | 2008-12-19 | 2022-06-13 | Vertex Pharmaceuticals Incorporated | Związki przydatne jako inhibitory kinazy atr |
| AU2010214101A1 (en) | 2009-02-11 | 2011-09-01 | Sunovion Pharmaceuticals Inc. | Histamine H3 inverse agonists and antagonists and methods of use thereof |
| JP2013504580A (ja) * | 2009-09-11 | 2013-02-07 | スノヴィオン ファーマシューティカルズ インコーポレイテッド | ヒスタミンｈ３インバースアゴニストおよびアンタゴニストとその使用方法 |
| JP2013526538A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2011143423A2 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| JP5836367B2 (ja) | 2010-05-12 | 2015-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| US9096584B2 (en) | 2010-05-12 | 2015-08-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2013529643A (ja) | 2010-06-23 | 2013-07-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用なピロロピラジン誘導体 |
| CA2832100A1 (en) | 2011-04-05 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Aminopyrazine compounds useful as inhibitors of tra kinase |
| BR112013028895A2 (pt) | 2011-05-10 | 2016-08-09 | Bayer Ip Gmbh | (tio)carbonilamidinas bicíclicas |
| WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| WO2012178123A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| AU2012315384B2 (en) | 2011-09-30 | 2017-08-10 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors |
| RU2018147217A (ru) | 2011-09-30 | 2019-01-18 | Вертекс Фармасьютикалз Инкорпорейтед | Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr |
| US8765751B2 (en) | 2011-09-30 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| IN2014KN00943A (pt) | 2011-09-30 | 2015-08-21 | Vertex Pharma | |
| US8841449B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013071090A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2776421A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2776429A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| JP5949070B2 (ja) * | 2012-04-03 | 2016-07-06 | Jsr株式会社 | 液晶配向剤、液晶配向膜及び液晶表示素子 |
| CN104582795B (zh) | 2012-04-05 | 2018-04-20 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物及其组合疗法 |
| DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
| US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| LT3418281T (lt) | 2012-12-07 | 2021-01-11 | Vertex Pharmaceuticals Inc. | Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui |
| WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| HUE046727T2 (hu) | 2013-12-06 | 2020-03-30 | Vertex Pharma | Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai |
| ES2777608T3 (es) | 2014-06-05 | 2020-08-05 | Vertex Pharma | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo |
| US11179394B2 (en) | 2014-06-17 | 2021-11-23 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of Chk1 and ATR inhibitors |
| US9758529B2 (en) * | 2015-02-11 | 2017-09-12 | Sunovion Pharmaceuticals Inc. | Fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analogs for treating CNS disorders |
| EP3286195A1 (en) | 2015-04-17 | 2018-02-28 | AbbVie Inc. | Indazolones as modulators of tnf signaling |
| UY36629A (es) | 2015-04-17 | 2016-11-30 | Abbvie Inc | Indazolonas como moduladores de la señalización de tnf |
| AR104291A1 (es) | 2015-04-17 | 2017-07-12 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
| US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| CA3119019C (en) * | 2015-12-10 | 2024-06-11 | Ptc Therapeutics, Inc. | Compounds and methods for treating huntington's disease |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| BR112019001407A2 (pt) | 2016-07-29 | 2019-07-09 | Sunovion Pharmaceuticals Inc. | compostos e composições e usos dos mesmos |
| EP4151627A1 (en) | 2017-06-05 | 2023-03-22 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| MX2020000523A (es) | 2017-08-02 | 2020-08-20 | Sunovion Pharmaceuticals Inc | Compuestos de isocromano y usos de los mismos. |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| CA3139821A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| WO2026058044A2 (en) * | 2024-09-11 | 2026-03-19 | Brandaris Therapeutics B.V. | Tricyclic 5-ht2ar agonists and uses thereof |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2479152A (en) | 1945-08-17 | 1949-08-16 | Eastman Kodak Co | 1,1'-dialkyl-3,3'-alkylenebenzimidazolocyanine salts |
| GB618889A (en) | 1946-07-23 | 1949-03-01 | Kodak Ltd | Improvements in the manufacture of n:n-alkylenebenzimidazocyanine dyes |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3642778A (en) | 1969-10-22 | 1972-02-15 | Robins Co Inc A H | Benzimidazo(1 2-d)(1 4)benzodiazepin-6(5h)-ones |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| DE2231560A1 (de) | 1972-06-28 | 1974-01-17 | Boehringer Sohn Ingelheim | Neue benzimidazolo-1,5-benzodiazepine |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4252816A (en) | 1979-12-03 | 1981-02-24 | Merck & Co., Inc. | Tetrahydro-1H-1,4-diazepino(1,7-a)benzimidazoles useful as analgesic agents |
| US4490463A (en) | 1983-03-03 | 1984-12-25 | Eastman Kodak Company | Alkanediyl bridged benzimidazolo monomethine cyanine dyes, processes for their preparation, and photographic emulsions and elements containing such dyes |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| FR2626740B1 (fr) | 1988-02-08 | 1990-10-19 | Xylochimie | Concentres emulsionnables de matieres biocides, les microemulsions aqueuses obtenues et l'application de ces microemulsions au traitement du bois |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| JPH04149180A (ja) | 1990-10-12 | 1992-05-22 | Fuji Photo Film Co Ltd | 含窒素複素環四級塩化合物及び該化合物の製造方法 |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| CA2153595A1 (en) | 1993-01-11 | 1994-07-21 | Anthony F. Garito | Polycyclic aromatic compounds having nonlinear optical properties |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| WO1996029331A1 (de) | 1995-03-20 | 1996-09-26 | Dr. Karl Thomae Gmbh | Imidazochinazoline, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| US5852191A (en) | 1995-06-07 | 1998-12-22 | Carnegie Mellon University | Rigidized monomethine cyanines |
| RU2106864C1 (ru) | 1995-10-23 | 1998-03-20 | Николай Серафимович Зефиров | Средство для лечения болезни альцгеймера |
| WO1998043649A2 (en) | 1997-03-28 | 1998-10-08 | Otsuka Pharmaceutical Co., Ltd. | Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b¿6? |
| US6605610B1 (en) | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
| ATE386024T1 (de) | 1997-12-31 | 2008-03-15 | Pfizer Prod Inc | Arylkondensierte azapolycyclische derivate |
| MXPA01011173A (es) | 1999-05-06 | 2002-04-24 | Neurogen Corp | 4-0x0-quinolin-3-carboxamidas sustituidas: ligandos del receptor cerebro de gaba. |
| JP3839999B2 (ja) | 1999-07-13 | 2006-11-01 | キヤノン株式会社 | 正帯電性トナー |
| US6515122B1 (en) | 1999-09-24 | 2003-02-04 | Lion Bioscience Ag | Tetracyclic benzimidazole derivatives and combinatorial libraries thereof |
| NZ521389A (en) * | 2000-03-14 | 2005-06-24 | Upjohn Co | 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds |
| DE10030685A1 (de) | 2000-06-23 | 2002-01-03 | Basf Ag | Verfahren zur Herstellung von aliphatischen Sulfonsäurechloriden aus Sulfonsäuren |
| CA2413702A1 (en) * | 2000-06-28 | 2002-01-03 | Teva Pharmaceuticals Industries Ltd. | Carvedilol |
| US6451520B1 (en) | 2000-07-29 | 2002-09-17 | Agfa-Gevaert | Color photographic silver halide material |
| MXPA05003477A (es) | 2002-10-03 | 2005-07-22 | Targegen Inc | Agentes vasculo-estaticos y metodos de uso de los mismos. |
| JP4736352B2 (ja) | 2003-06-16 | 2011-07-27 | 三菱化学株式会社 | 電界効果トランジスタ |
| US20050026910A1 (en) | 2003-07-25 | 2005-02-03 | The Regents Of The University Of Michigan | Method of treating viral diseases |
| GB0324159D0 (en) * | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
| US20050239767A1 (en) | 2003-10-28 | 2005-10-27 | Chan Michael K | Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands |
| RU2283108C2 (ru) | 2003-12-08 | 2006-09-10 | Сергей Олегович Бачурин | ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| US7419511B2 (en) | 2004-09-13 | 2008-09-02 | L'oreal, S.A. | Compositions comprising at least one substituted carbocyanin derivative, processes for treating keratin fibers using them, device therefor and uses thereof |
| DE602005005941D1 (de) | 2005-02-10 | 2008-05-21 | Bioprojet Soc Civ | Monohydrochloridsalz von 1-Ä3-Ä3-(4-Chlorophenyl)propoxyÜpropylÜ-piperidin |
| US20060217370A1 (en) | 2005-02-18 | 2006-09-28 | Ethan Burstein | Compounds useful for the treatment and prevention of pain and screening methods therefor |
| WO2007041697A2 (en) | 2005-10-04 | 2007-04-12 | Medivation, Inc. | Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease |
| ES2333672T3 (es) * | 2005-12-09 | 2010-02-25 | F. Hoffmann-La Roche Ag | Derivados de amida triciclica para tratamiento de obesidad. |
| RU2338537C2 (ru) | 2006-01-25 | 2008-11-20 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| FR2897061B1 (fr) | 2006-02-03 | 2010-09-03 | Sanofi Aventis | Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique. |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| CA2664098A1 (en) | 2006-09-20 | 2008-03-27 | Medivation Neurology, Inc. | Compounds and method for treating canine cognitive dysfunction syndrome |
| US20100099700A1 (en) | 2006-09-20 | 2010-04-22 | David Hung | Hydrogenated pyrido (4,3-b) indoles for treating amyotrophic lateral sclerosis (als) |
| EP2420235A1 (en) | 2006-10-27 | 2012-02-22 | Medivation Neurology, Inc. | Methods and combination therapies for treating alzheimer's disease |
| RU2334514C1 (ru) | 2006-12-01 | 2008-09-27 | Институт физиологически активных веществ Российской Академии наук | СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| RU2340342C2 (ru) | 2006-12-07 | 2008-12-10 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| US8541437B2 (en) | 2007-04-05 | 2013-09-24 | Alla Chem, Llc | Substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles, methods for the production and use thereof |
| PL1990355T3 (pl) | 2007-05-11 | 2013-01-31 | Cognis Ip Man Gmbh | Zastosowanie adduktów tlenku propylenu |
| MX2009012788A (es) | 2007-05-25 | 2010-01-14 | Medivation Neurology Inc | Metodos y composiciones para estimular celulas. |
| RU2338533C1 (ru) | 2007-06-28 | 2008-11-20 | Сергей Олегович Бачурин | СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| CA2719824A1 (en) | 2007-08-01 | 2009-02-05 | Medivation Neurology, Inc. | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
| AU2008302751A1 (en) | 2007-09-20 | 2009-03-26 | D2E, Llc | Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use |
| WO2009039420A1 (en) | 2007-09-21 | 2009-03-26 | Medivation Neurology, Inc. | Methods and compositions for treating neuronal death mediated ocular diseases |
| RU2007139634A (ru) | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| EP2240485B1 (en) | 2008-01-22 | 2014-10-15 | Takeda Pharmaceutical Company Limited | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them |
| RU2544856C2 (ru) | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| JP2009203311A (ja) | 2008-02-27 | 2009-09-10 | Shikoku Chem Corp | 熱硬化性樹脂組成物 |
| WO2009111540A1 (en) | 2008-03-04 | 2009-09-11 | Medivation Neurology, Inc. | Methods for preparing pyridylethyl-substituted carbolines |
| TWI450900B (zh) | 2008-03-24 | 2014-09-01 | Medivation Technologies Inc | 橋聯雜環化合物及使用方法 |
| TWI443098B (zh) | 2008-03-24 | 2014-07-01 | Medivation Technologies Inc | 吡啶并〔３，４－ｂ〕吲哚及使用方法 |
| WO2009135091A1 (en) | 2008-04-30 | 2009-11-05 | Medivation Technologies, Inc. | Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions |
| CN102316732B (zh) | 2008-10-31 | 2015-04-01 | 梅迪维新技术公司 | 氮杂*并[4,5-b]吲哚以及使用方法 |
| AR073923A1 (es) | 2008-10-31 | 2010-12-09 | Medivation Technologies Inc | Pirido( 4,3-b) indoles que contienen restos rigidos |
| JP5801193B2 (ja) | 2008-11-03 | 2015-10-28 | エルジー・ケム・リミテッド | 新しい含窒素複素環化合物およびそれを用いた有機電子素子 |
| AU2010214101A1 (en) | 2009-02-11 | 2011-09-01 | Sunovion Pharmaceuticals Inc. | Histamine H3 inverse agonists and antagonists and methods of use thereof |
| JP5347662B2 (ja) | 2009-04-03 | 2013-11-20 | ソニー株式会社 | 有機電界発光素子および表示装置 |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| WO2010127177A1 (en) | 2009-04-29 | 2010-11-04 | Medivation Technologies, Inc. | Pyrido [4,3-b] indoles and methods of use |
| WO2011019417A1 (en) | 2009-04-29 | 2011-02-17 | Medivation Technologies, Inc. | Pyrido [4, 3-b] indoles and methods of use |
| KR20120035183A (ko) | 2009-06-10 | 2012-04-13 | 선오비온 파마슈티컬스 인코포레이티드 | 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법 |
| WO2011014695A1 (en) | 2009-07-29 | 2011-02-03 | Medivation Technologies, Inc. | New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b] indoles and methods of use |
| JP2013504580A (ja) | 2009-09-11 | 2013-02-07 | スノヴィオン ファーマシューティカルズ インコーポレイテッド | ヒスタミンｈ３インバースアゴニストおよびアンタゴニストとその使用方法 |
-
2010
- 2010-02-11 AU AU2010214101A patent/AU2010214101A1/en not_active Abandoned
- 2010-02-11 US US12/704,460 patent/US8063032B2/en not_active Expired - Fee Related
- 2010-02-11 WO PCT/US2010/000335 patent/WO2010093425A1/en not_active Ceased
- 2010-02-11 EP EP10705454A patent/EP2396327A1/en not_active Withdrawn
- 2010-02-11 SG SG2011057759A patent/SG173639A1/en unknown
- 2010-02-11 CN CN2010800159234A patent/CN102388043A/zh active Pending
- 2010-02-11 RU RU2011137419/04A patent/RU2011137419A/ru unknown
- 2010-02-11 JP JP2011550123A patent/JP2012517471A/ja active Pending
- 2010-02-11 CA CA2752073A patent/CA2752073A1/en not_active Abandoned
- 2010-02-11 BR BRPI1008020A patent/BRPI1008020A2/pt not_active Application Discontinuation
- 2010-02-11 KR KR1020117021375A patent/KR20110132564A/ko not_active Withdrawn
-
2011
- 2011-08-07 IL IL214501A patent/IL214501A0/en unknown
- 2011-09-29 US US13/249,166 patent/US8404670B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8063032B2 (en) | 2011-11-22 |
| SG173639A1 (en) | 2011-09-29 |
| WO2010093425A1 (en) | 2010-08-19 |
| US20120022050A1 (en) | 2012-01-26 |
| CA2752073A1 (en) | 2010-08-19 |
| JP2012517471A (ja) | 2012-08-02 |
| EP2396327A1 (en) | 2011-12-21 |
| US20100204214A1 (en) | 2010-08-12 |
| CN102388043A (zh) | 2012-03-21 |
| US8404670B2 (en) | 2013-03-26 |
| AU2010214101A1 (en) | 2011-09-01 |
| IL214501A0 (en) | 2011-09-27 |
| KR20110132564A (ko) | 2011-12-08 |
| RU2011137419A (ru) | 2013-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1012097A2 (pt) | antagonistas e antagonistas inversos de histamina h3 e métodos de uso dos mesmos. | |
| BRPI0917891A2 (pt) | antagonistas de pd-1 e métodos de utilização dos mesmos | |
| BRPI1014544A2 (pt) | anticorpors anti-il-17f e metodos de uso dos mesmos | |
| BR112012024120A2 (pt) | sarms e método de uso dos mesmos | |
| BRPI0909077A2 (pt) | Artigos multicamadas e métodos de preparo e uso dos mesmos | |
| BR112013017980A2 (pt) | polipeptídeos de imunoglobulina marcado com aldeído e método de uso dos mesmos | |
| BRPI1012333A2 (pt) | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso | |
| BRPI1010024A2 (pt) | derivados de aminopirrolidinona e uso dos mesmos | |
| BR112012001316A2 (pt) | inibidores de pequena molécula potente de autofagia, e métodos de uso dos mesmos. | |
| IL214501A0 (en) | Histamine h3 inverse agonists and antagonists and methods of use thereof | |
| BRPI1015315A2 (pt) | composto heterocíclico fundido e uso dos mesmos | |
| BR112014012590A2 (pt) | anticorpos anti-cd98 e métodos de uso dos mesmos | |
| BR112013014321A2 (pt) | moduladores inovadores e métodos de uso | |
| BRPI1012676A2 (pt) | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso | |
| BRPI1012560A2 (pt) | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso | |
| BRPI0916269A2 (pt) | dispositivo de modificação de tecido e seu método de uso | |
| BRPI0815811A2 (pt) | Derivados de indol substituído e métodos de uso dos mesmos | |
| PL2648726T3 (pl) | Policykliczny antagonista lpa1 i jego zastosowania | |
| BR112013013167A2 (pt) | inibidores de bromodomínio e usos dos mesmos | |
| BRPI0915717A2 (pt) | ferramenta de avaliação de cascalho e métodos de uso | |
| PT2616087T (pt) | Fagos antibacterianos, péptidos fágicos e métodos de utilização dos mesmos | |
| BR112014009006A2 (pt) | compostos heterocíclicos e métodos de uso dos mesmos | |
| BRPI1006857A2 (pt) | agentes de limpeza para limpeza de poços e métodos de uso dos mesmos | |
| BRPI0907236A2 (pt) | inibidores de proteína quinase e uso dos mesmos | |
| BR112014001991A2 (pt) | certos inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |